Jürgen Floege
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jürgen Floege has a total of 389 co-authors. Here are the top co-authors by number of shared publications:
- Brad H. Rovin
Internal Medicine/Nephrology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
10 shared publications - Jonathan Barratt
Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom
8 shared publications Heather N. Reich
Divsion of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
7 shared publicationsJonathan Barratt
6 shared publicationsAdrian Liew
5 shared publicationsH. Terence Cook
Department of Immunology and Inflammation, Imperial College London, London, UK
5 shared publications
Latest Publications
- 9 October 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Epithelial PDGF-C Contributes to Crescentic Glomerulonephritis and FSGS in Part via Activation of Parietal Epithelial Cells
Key Points: PDGF-C was induced in activated parietal epithelial cells/podocytes along with PDGFR α in parietal epithelial cells/periglomerular cells in mouse models of crescentic glomerulonephritis/FSGS and human kidney samples. PDGF-C contributed in part to parietal epithelial cell activation and disease progression both in vitro and in all in vivo models of crescentic glomerulonephritis and FSGS. Presented in vitro and in vivo data supported a feed-forward interaction between PDGF-C and FOXM1. Background: Activated parietal epithelial cells (PECs) and podocytes are key effector cells in the development of crescentic glomerulonephritis and FSGS. PDGF-C has been found to be important for tubulointerstitial fibrosis development, but its relevance for crescentic glomerulonephritis and FSGS was previously unknown. Methods: To address this, expression analyses for both PDGF-C and its receptor PDGFR α were carried out in mouse and human kidney tissues. To further elucidate a functional role of PDGF-C, the murine nephrotoxic nephritis model of crescentic glomerulonephritis was induced in ( 1 ) Pdgfc -deficient mice, ( 2 ) mice treated with a neutralizing PDGF-C antibody, and ( 3 ) Pax8-cre::Pdgfc fl / fl mice with conditional Pdgfc deletion in kidney epithelial cells. We also subjected the collapsing FSGS model of the anti-Thy1.1 transgenic mouse to pharmacologic PDGF-C inhibition. The studies were supplemented by PEC in vitro analyses. Results: Our data showed that PDGF-C was upregulated in PECs and expressed de novo in podocytes under disease conditions. It promoted the proliferation and activation of primary as well as conditionally immortalized PECs in vitro . In both the genetic and pharmacologic PDGF-C intervention studies in murine crescentic glomerulonephritis and FSGS, significant improvements in glomerular crescent formation, glomerular sclerosis, renal inflammation, and kidney function parameters were observed upon PDGF-C deficiency or antagonism. Mechanistically, transcription factor FOXM1 was identified as a mediator of disease-related PDGF-C expression in PECs. Conclusions: Our studies identified epithelial PDGF-C as a contributor to disease progression in crescentic glomerulonephritis and FSGS, acting in part through the activation of PECs.
- 9 October 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Epithelial PDGF-C Contributes to Crescentic Glomerulonephritis and FSGS in Part via Activation of Parietal Epithelial Cells
Key Points: PDGF-C was induced in activated parietal epithelial cells/podocytes along with PDGFR α in parietal epithelial cells/periglomerular cells in mouse models of crescentic glomerulonephritis/FSGS and human kidney samples. PDGF-C contributed in part to parietal epithelial cell activation and disease progression both in vitro and in all in vivo models of crescentic glomerulonephritis and FSGS. Presented in vitro and in vivo data supported a feed-forward interaction between PDGF-C and FOXM1. Background: Activated parietal epithelial cells (PECs) and podocytes are key effector cells in the development of crescentic glomerulonephritis and FSGS. PDGF-C has been found to be important for tubulointerstitial fibrosis development, but its relevance for crescentic glomerulonephritis and FSGS was previously unknown. Methods: To address this, expression analyses for both PDGF-C and its receptor PDGFR α were carried out in mouse and human kidney tissues. To further elucidate a functional role of PDGF-C, the murine nephrotoxic nephritis model of crescentic glomerulonephritis was induced in ( 1 ) Pdgfc -deficient mice, ( 2 ) mice treated with a neutralizing PDGF-C antibody, and ( 3 ) Pax8-cre::Pdgfc fl / fl mice with conditional Pdgfc deletion in kidney epithelial cells. We also subjected the collapsing FSGS model of the anti-Thy1.1 transgenic mouse to pharmacologic PDGF-C inhibition. The studies were supplemented by PEC in vitro analyses. Results: Our data showed that PDGF-C was upregulated in PECs and expressed de novo in podocytes under disease conditions. It promoted the proliferation and activation of primary as well as conditionally immortalized PECs in vitro . In both the genetic and pharmacologic PDGF-C intervention studies in murine crescentic glomerulonephritis and FSGS, significant improvements in glomerular crescent formation, glomerular sclerosis, renal inflammation, and kidney function parameters were observed upon PDGF-C deficiency or antagonism. Mechanistically, transcription factor FOXM1 was identified as a mediator of disease-related PDGF-C expression in PECs. Conclusions: Our studies identified epithelial PDGF-C as a contributor to disease progression in crescentic glomerulonephritis and FSGS, acting in part through the activation of PECs.
- 6 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 546-547
The 4-hit hypothesis in IgA nephropathy is getting more complex
- 6 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 546-547
The 4-hit hypothesis in IgA nephropathy is getting more complex
- 20 May 2026
- Published by Elsevier in Kidney International
- Vol. 109 (6) , 1091-1094
Beyond galactose-deficient IgA1: reconsidering IgA2 as a pathogenic driver in IgA nephropathy
- 20 May 2026
- Published by Elsevier in Kidney International
- Vol. 109 (6) , 1091-1094
Beyond galactose-deficient IgA1: reconsidering IgA2 as a pathogenic driver in IgA nephropathy
- Top Cited PapersOpen Access
- 27 March 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 548-565
Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- 27 March 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 548-565
Top Cited PapersOpen AccessTargeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- Top Cited PapersOpen Access
- 26 March 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 502-507
Complement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary
- 26 March 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 502-507
Top Cited PapersOpen AccessComplement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary
- Open Access
- 3 March 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (5)
Simultaneous or sequential treatment of IgA nephropathy - specific disease drivers and non-specific consequences of nephron loss?
The expanding therapeutic armamentarium for IgA nephropathy (IgAN) has brought to the forefront a key strategic dilemma: whether to intervene simultaneously on IgAN-specific pathogenic mechanisms and the downstream, non-specific consequences of nephron loss, or to follow a sequential, stepwise approach in which therapies are added only as residual risk becomes evident. This debate article contrasts these philosophies. Proponents of early, combined treatment, in line with KDIGO 2025 guidance, argue that the traditional paradigm of first maximizing ‘supportive’ care—renin–angiotensin system blockade, strict blood pressure and sodium control, and more recently SGLT2 inhibitors and mineralocorticoid receptor antagonists—before initiating immunosuppressive or other disease-directed agents embeds harmful delay. They emphasize that IgAN is driven by continuous immune activity, with ongoing production of pathogenic IgA, immune complex formation, complement activation, and glomerular injury that proceeds even when proteinuria is hemodynamically reduced. Once a critical threshold of nephron loss is crossed, self-perpetuating hyperfiltration, fibrosis, and microvascular rarefaction limit reversibility. Advocates of a more sequential strategy highlight heterogeneity in disease course, the risks and costs of polypharmacy, and the need for individualized escalation based on dynamic risk assessment. Together, the opposing yet complementary viewpoints underscore that future algorithms will likely integrate baseline risk stratification, evolving biomarkers of immune activity and chronic damage, and patient preferences to balance early, comprehensive disease control against overtreatment and toxicity in IgAN.
- 3 March 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (5)
Open AccessSimultaneous or sequential treatment of IgA nephropathy - specific disease drivers and non-specific consequences of nephron loss?
The expanding therapeutic armamentarium for IgA nephropathy (IgAN) has brought to the forefront a key strategic dilemma: whether to intervene simultaneously on IgAN-specific pathogenic mechanisms and the downstream, non-specific consequences of nephron loss, or to follow a sequential, stepwise approach in which therapies are added only as residual risk becomes evident. This debate article contrasts these philosophies. Proponents of early, combined treatment, in line with KDIGO 2025 guidance, argue that the traditional paradigm of first maximizing ‘supportive’ care—renin–angiotensin system blockade, strict blood pressure and sodium control, and more recently SGLT2 inhibitors and mineralocorticoid receptor antagonists—before initiating immunosuppressive or other disease-directed agents embeds harmful delay. They emphasize that IgAN is driven by continuous immune activity, with ongoing production of pathogenic IgA, immune complex formation, complement activation, and glomerular injury that proceeds even when proteinuria is hemodynamically reduced. Once a critical threshold of nephron loss is crossed, self-perpetuating hyperfiltration, fibrosis, and microvascular rarefaction limit reversibility. Advocates of a more sequential strategy highlight heterogeneity in disease course, the risks and costs of polypharmacy, and the need for individualized escalation based on dynamic risk assessment. Together, the opposing yet complementary viewpoints underscore that future algorithms will likely integrate baseline risk stratification, evolving biomarkers of immune activity and chronic damage, and patient preferences to balance early, comprehensive disease control against overtreatment and toxicity in IgAN.
- Open Access
- 5 December 2025
- Vol. 19 (1)
The 2025 KDIGO guideline on the management of nephrotic syndrome in children: a comment of the European Renal Association Immunonephrology Working Group
Despite advances and therapeutic progress, nephrotic syndrome (NS) in childhood remains challenging due to its heterogeneous presentation, variable response to treatment and the potential of adverse long-term kidney outcomes. The recently published KDIGO 2025 clinical practice guideline for the management of NS in children refines the definitions of relapse, infrequently- and frequently-relapsing NS and steroid-resistant NS. Herein we describe the revised definitions, summarize the key updates of the KDIGO 2025 guidelines and comment on the new treatment algorithm from a European viewpoint, highlighting the need for individualized approaches to minimize toxicity and optimize long-term kidney outcomes in NS in children.
- 5 December 2025
- Vol. 19 (1)
Open AccessThe 2025 KDIGO guideline on the management of nephrotic syndrome in children: a comment of the European Renal Association Immunonephrology Working Group
Despite advances and therapeutic progress, nephrotic syndrome (NS) in childhood remains challenging due to its heterogeneous presentation, variable response to treatment and the potential of adverse long-term kidney outcomes. The recently published KDIGO 2025 clinical practice guideline for the management of NS in children refines the definitions of relapse, infrequently- and frequently-relapsing NS and steroid-resistant NS. Herein we describe the revised definitions, summarize the key updates of the KDIGO 2025 guidelines and comment on the new treatment algorithm from a European viewpoint, highlighting the need for individualized approaches to minimize toxicity and optimize long-term kidney outcomes in NS in children.
- Open Access
- 4 December 2025
- Published by Elsevier in Kidney International Reports
- Vol. 11 (2) , 103705
Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation
- 4 December 2025
- Published by Elsevier in Kidney International Reports
- Vol. 11 (2) , 103705
Open AccessComplement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation
- Open Access
- 19 November 2025
- Published by Elsevier in Kidney International
- Vol. 108 (6) , 1197-1198
Corrigendum to “Treatment of patients with IgA nephropathy: a call for a new paradigm.” Kidney International 2025;107:640–651
- 19 November 2025
- Published by Elsevier in Kidney International
- Vol. 108 (6) , 1197-1198
Open AccessCorrigendum to “Treatment of patients with IgA nephropathy: a call for a new paradigm.” Kidney International 2025;107:640–651
- Open Access
- 24 October 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (11) , sfaf328
Age-adapted versus age-independent eGFR thresholds to diagnose CKD: integrating the debate and charting a balanced path forward
The debate over whether to use age-adapted or age-independent estimated glomerular filtration rate (eGFR) cut-offs for diagnosing chronic kidney disease (CKD) reflects a fundamental tension between physiological understanding and clinical pragmatism. Age-adapted proponents highlight robust evidence that GFR declines naturally with age, with many healthy older adults falling below the traditional 60 ml/min/1.73 m2 threshold. They argue that fixed cut-offs risk overdiagnosing CKD in the elderly, potentially leading to unnecessary anxiety and treatment, while underrecognizing risk in younger individuals whose GFRs are abnormal for their age. Physiological and longitudinal studies support this view, suggesting age-specific percentiles may better reflect true pathology. Conversely, advocates for age-independent thresholds emphasize that age-related GFR decline is not benign. Large epidemiological studies show that older adults with an eGFR of 45–59 ml/min/1.73 m2 are at increased risk of kidney failure, cardiovascular events and mortality, even in the absence of albuminuria. They caution that redefining CKD based on age could exclude high-risk older adults from beneficial therapies and research and that ‘healthy’ reference populations may harbour undiagnosed disease. A balanced approach recognizes the physiological realities of aging while not ignoring the clinical risks associated with reduced kidney function in older adults. Individualized risk prediction tools and shared decision-making can help tailor diagnosis and management. Ultimately, moving beyond arbitrary thresholds toward a patient-centred, risk-based strategy may best serve individuals across their lifespans, ensuring that CKD diagnosis and care are both scientifically sound and clinically meaningful.
- 24 October 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (11) , sfaf328
Open AccessAge-adapted versus age-independent eGFR thresholds to diagnose CKD: integrating the debate and charting a balanced path forward
The debate over whether to use age-adapted or age-independent estimated glomerular filtration rate (eGFR) cut-offs for diagnosing chronic kidney disease (CKD) reflects a fundamental tension between physiological understanding and clinical pragmatism. Age-adapted proponents highlight robust evidence that GFR declines naturally with age, with many healthy older adults falling below the traditional 60 ml/min/1.73 m2 threshold. They argue that fixed cut-offs risk overdiagnosing CKD in the elderly, potentially leading to unnecessary anxiety and treatment, while underrecognizing risk in younger individuals whose GFRs are abnormal for their age. Physiological and longitudinal studies support this view, suggesting age-specific percentiles may better reflect true pathology. Conversely, advocates for age-independent thresholds emphasize that age-related GFR decline is not benign. Large epidemiological studies show that older adults with an eGFR of 45–59 ml/min/1.73 m2 are at increased risk of kidney failure, cardiovascular events and mortality, even in the absence of albuminuria. They caution that redefining CKD based on age could exclude high-risk older adults from beneficial therapies and research and that ‘healthy’ reference populations may harbour undiagnosed disease. A balanced approach recognizes the physiological realities of aging while not ignoring the clinical risks associated with reduced kidney function in older adults. Individualized risk prediction tools and shared decision-making can help tailor diagnosis and management. Ultimately, moving beyond arbitrary thresholds toward a patient-centred, risk-based strategy may best serve individuals across their lifespans, ensuring that CKD diagnosis and care are both scientifically sound and clinically meaningful.